Other complications and diabetes-associated conditions in children and adolescents

Pediatric Diabetes

Volumn 15, Issue SUPPL.20, 2014, Pages 270-278

  Kordonouri, Olga ^a   Klingensmith, Georgeanna ^b   Knip, Mikael ^c   Holl, Reinhard W ^d   Aanstoot, Henk Jan ^f   Menon, Puthezhath S N ^e   Craig, Maria E ^g,h,i  

^a Children's Hospital Auf der Bult   (Germany)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF ULM   (Germany)

^e Center for Pediatric and Adolescent Diabetes Care and Research   (Netherlands)

^f Jaber AL Ahmed Armed Forces Hospital   (Kuwait)

^g CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Celiac disease; Child; Complications; Thyroid disease; Type 1 diabetes

Indexed keywords

ADOLESCENT; AUTOIMMUNITY; CHILD; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FAMILY; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOLOGY; INFANT; INTERNATIONAL COOPERATION; MEDICINE; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; PEDIATRICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRESCHOOL CHILD; SELF CARE; TRENDS;

ADOLESCENT; ADOLESCENT MEDICINE; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FAMILY; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; INTERNATIONAL AGENCIES; PATIENT EDUCATION AS TOPIC; PEDIATRICS; SELF CARE; SOCIETIES, SCIENTIFIC;

EID: 84906835068     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12183     Document Type: Article

References (116)

1. Bognetti E, Riva MC, Bonfanti R, Meschi F, Viscardi M, Chiumello G. Growth changes in children and adolescents with short-term diabetes. Diabetes Care 1998: 21: 1226-1229.
2. Ljungkrantz M, Ludvigsson J, Samuelsson U. Type 1 diabetes: increased height and weight gains in early childhood. Pediatr Diabetes 2008: 9: 50-56.
3. Lamb MM, Yin X, Zerbe GO et al. Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia 2009: 52: 2064-2071.
4. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Dabelea D. Childhood growth and age at diagnosis with type 1 diabetes in Colorado young people. Diabet Med 2009: 26: 961-967.
5. Islam ST, Abraham A, Donaghue KC et al. Plateau of adiposity in Australian children diagnosed with type 1 diabetes: a 20-year study. Diabet Med 2014: 31(6):686-690.
6. Beyerlein A, Thiering E, Pflueger M et al. Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children. Pediatr Diabetes 2014: Feb 21 [epub ahead of print].
7. Knerr I, Wolf J, Reinehr T, Stachow R, Grabert M, Schober E, et al. The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9, 248 German and Austrian children with type 1 diabetes mellitus. Diabetologia. 2005; 48:2501-2504.
8. Clarke SL, Craig ME, Garnett SP et al. Increased adiposity at diagnosis in younger children with type 1 diabetes does not persist. Diabetes Care 2006: 29: 1651-1653.
9. Couper JJ, Beresford S, Hirte C et al. Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care 2009: 32: 94-99.
10. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond). 2009; 33:716-726.
11. Gunczler P, Lanes R. Poor metabolic control decreases the growth velocity of diabetic children. Diabetes Care. 1999; 22:1012.
12. Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care 2011: 34: 2368-2373.
13. Bonfig W, Kapellen T, Dost A et al. Growth in children and adolescents with type 1 diabetes. J Pediatr 2012: 160: 900-3.e2.
14. Giannini C, Mohn A, Chiarelli F. Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma. Int J Endocrinol 2014: 2014: 265954.
15. Donaghue KC, Kordonouri O, Chan A, Silink M. Secular trends in growth in diabetes: are we winning? Arch Dis Child 2003: 88: 151-154.
16. Fitzpatrick E, Cotoi C, Quaglia A, Sakellariou S, Ford-Adams ME, Hadzic N. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre. Arch Dis Child 2014: 99: 354-357.
17. Kim MS, Quintos JB. Mauriac syndrome: growth failure and type 1 diabetes mellitus. Pediatr Endocrinol Rev 2008: 5 (Suppl. 4): 989-993.
18. Bonfig W, Molz K, Woelfle J, Hofer SE, Hauffa BP, Schoenau E, et al. Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency. J Pediatr. 2013; 163:1095-8 e4.
19. Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab. 1990; 71:1356-1362.
20. Holl RW, Siegler B, Scherbaum WA, Heinze E. The serum growth hormone-binding protein is reduced in young patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993; 76:165-167.
21. Hedman CA, Frystyk J, Lindström T, Chen JW, Flyvbjerg A, Ørskov H, et al. Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab. 2004; 89:6305-6319.
22. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012; 41:425-443, vii-viii.
23. Kim MS, Lee DY. Serum insulin-like growth factor-binding protein-3 level correlated with glycemic control and lipid profiles in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab. 2014.
24. Palta M, LeCaire T, Sadek-Badawi M, Herrera V, Danielson KK. The trajectory of IGF-1 across age and duration of type 1 diabetes. Diabetes Metab Res Rev. 2014.
25. Fröhlich-Reiterer EE, Rosenbauer J, Bechtold-Dalla Pozza S et al. Predictors of increasing BMI during the course of diabetes in children and adolescents with type 1 diabetes: data from the German/Austrian DPV multicentre survey. Arch Dis Child 2014: May 8 [epub ahead of print].
26. DCCT Research Group (Diabetes Control and Complications Trial Research Group). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
27. Holl RW, Grabert M, Sorgo W, Heinze E, Debatin KM. Contributions of age, gender and insulin administration to weight gain in subjects with IDDM. Diabetologia 1998: 41: 542-547.
28. Olmsted MP, Colton PA, Daneman D, Rydall AC, Rodin GM. Prediction of the onset of disturbed eating behavior in adolescent girls with type 1 diabetes. Diabetes Care. 2008; 31:1978-1982.
29. Young V, Eiser C, Johnson B, Brierley S, Epton T, Elliott J, et al. Eating problems in adolescents with Type 1 diabetes: a systematic review with meta-analysis. Diabet Med. 2013; 30:189-198.
30. Codner E, Soto N, Lopez P et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006: 91: 2250-2256.
31. Codner E, Cassorla F. Puberty and ovarian function in girls with type 1 diabetes mellitus. Horm Res 2009: 71: 12-21.
32. Cho YH, Craig ME, Srinivasan S et al. Heart rate variability in pubertal girls with type 1 diabetes: its relationship with glycaemic control, insulin resistance and hyperandrogenism. Clin Endocrinol (Oxf) 2014: 80: 818-824.
33. Codner E, Iñíguez G, López P et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr 2013: 80: 343-349.
34. Nathan N, Sullivan SD. The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). Curr Pharm Biotechnol 2014: Mar 30 [Epub ahead of print].
35. Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res 2014: Mar 4. pii: S1931-5244(14)00078-4.
36. Watkins RA, Evans-Molina C, Blum JS, Dimeglio LA. Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic review. Transl Res. 2014.
37. Warncke K, Frohlich-Reiterer EE, Thon A, Hofer SE, Wiemann D, Holl RW. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28, 671 patients from the German/Austrian DPV-Wiss database. Diabetes Care 2010: 33: 2010-2012.
38. Jonsdottir B, Andersson C, Carlsson A et al. Thyroid autoimmunity in relation to islet autoantibodies and HLA-DQ genotype in newly diagnosed type 1 diabetes in children and adolescents. Diabetologia 2013: 56: 1735-1742.
39. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of shared genetics and pathogenesis in autoimmune diseases. Nat Rev Endocrinol 2013: 9: 646-659.
40. Sumnik Z, Kolouskova S, Malcova H et al. High prevalence of coeliac disease in siblings of children with type 1 diabetes. Eur J Pediatr 2005: 164: 9-12.
41. Mohn A, Di Michele S, Faricelli R, Martinotti S, Chiarelli F. Increased frequency of subclinical hypothyroidism and thyroid-associated antibodies in siblings of children and adolescents with type 1 diabetes mellitus. Eur J Endocrinol 2005: 153: 717-718.
42. Sosenko JM, Skyler JS, Palmer JP et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013: 36: 2615-2620.
43. Denzer C, Karges B, Näke A et al. Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus. Eur J Endocrinol 2013: 168: 601-608.
44. Shun CB, Donaghue KC, Phelan H, Twigg SM, Craig ME. Thyroid autoimmunity in type 1 diabetes: systematic review and meta-analysis. Diabet Med 2014: 31: 126-135.
45. Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 2005: 28: 2170-2175.
46. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child 2005: 90: 411-414.
47. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009: 360: 1574-1575.
48. Larsson K, Carlsson A, Cederwall E et al. Annual screening detects celiac disease in children with type 1 diabetes. Pediatr Diabetes 2008: 9: 354-359.
49. Salardi S, Volta U, Zucchini S et al. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr 2008: 46: 612-614.
50. Fröhlich-Reiterer EE, Kaspers S, Hofer S et al. Anthropometry, metabolic control, and follow-up in children and adolescents with type 1 diabetes mellitus and biopsy-proven celiac disease. J Pediatr 2011: 158: 589-93.e2.
51. Pham-Short A, Donaghue KC, Ambler G, Chan AK, Craig ME. Coeliac disease in type 1 diabetes from 1990 to 2009: higher incidence in young children after longer diabetes duration. Diabet Med 2012: 29: e286-e289.
52. Cerutti F, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes. Diabetes Care 2004: 27: 1294-1298.
53. Mohn A, Cerruto M, Iafusco D et al. Celiac disease in children and adolescents with type I diabetes: importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001: 32: 37-40.
54. Giersiepen K, Lelgemann M, Stuhldreher N et al. Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr Gastroenterol Nutr 2012: 54: 229-241.
55. Mothes T. Deamidated gliadin peptides as targets for celiac disease-specific antibodies. Adv Clin Chem 2007: 44: 35-63.
56. Husby S, Koletzko S, Korponay-Szabó IR et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012: 54: 136-160.
57. Romanos J, Rosén A, Kumar V et al. Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants. Gut 2014: 63: 415-422.
58. Doolan A, Donaghue K, Fairchild J, Wong M, Williams AJ. Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes. Diabetes Care. 2005; 28:806-819.
59. Kurien M, Leeds JS, Hopper AD et al. Serological testing for coeliac disease in type 1 diabetes mellitus: is immunoglobulin A level measurement necessary? Diabet Med 2013: 30: 840-845.
60. Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997: 131: 306-308.
61. Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995: 9: 273-293.
62. Murch S, Jenkins H, Auth M et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. Arch Dis Child 2013: 98: 806-811.
63. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. Gastroenterology ACo. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013: 108: 656-676; quiz 77.
64. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 2002: 25: 1117-1122.
65. Saukkonen T, Vaisanen S, Akerblom HK, Savilahti E. Coeliac disease in children and adolescents with type 1 diabetes: a study of growth, glycaemic control, and experiences of families. Acta Paediatr 2002: 91: 297-302.
66. Margoni D, Chouliaras G, Duscas G et al. Bone health in children with celiac disease assessed by dual x-ray absorptiometry: effect of gluten-free diet and predictive value of serum biochemical indices. J Pediatr Gastroenterol Nutr 2012: 54: 680-684.
67. Mollazadegan K, Kugelberg M, Montgomery SM, Sanders DS, Ludvigsson J, Ludvigsson JF. A population-based study of the risk of diabetic retinopathy in patients with type 1 diabetes and celiac disease. Diabetes Care 2013: 36: 316-321.
68. Pham-Short A, Donaghue CK, Ambler G et al. Early elevation of albumin excretion rate is associated with poor gluten-free diet adherence in young people with coeliac disease and diabetes. Diabet Med 2014: 31: 208-212.
69. Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003: 20: 207-210.
70. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med 2008: 75: 772, 774, 776-777 passim.
71. Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmunol Photomed 2013: 29: 34-40.
72. Peterson P, Salmi H, Hyöty H et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol 1997: 82: 37-42.
73. De Block CE, De Leeuw IH, Vertommen JJ et al. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin Exp Immunol 2001: 126: 236-241.
74. Baker P, Fain P, Kahles H et al. Genetic determinants of 21-hydroxylase autoantibodies amongst patients of the type 1 diabetes Genetics Consortium. J Clin Endocrinol Metab 2012: 97: E1573-E1578.
75. Triolo TM, Baschal EE, Armstrong TK et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009: 94: 4517-4523.
76. Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev 2014: 13: 85-89.
77. Aaltonen J, Björses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994: 8: 83-87.
78. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990: 322: 1829-1836.
79. Brandão Neto RA, de Carvalho JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). Autoimmun Rev 2014: 13: 408-411.
80. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003: 88: 2983-2992.
81. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010: 6: 270-277.
82. Oda JM, Hirata BK, Guembarovski RL, Watanabe MA. Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases. J Genet 2013: 92: 163-171.
83. Sawatkar GU, Kanwar AJ, Dogra S, Bhadada SK, Dayal D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. Br J Dermatol 2014: doi: 10.1111/bjd.13077. Apr 28. [Epub ahead of print].
84. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care 2001: 24: 174.
85. Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Diabetes Care 2005: 28: 2983.
86. Babiker A, Datta V. Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child 2011: 96: 101-102.
87. Salgin B, Meissner T, Beyer P et al. Lipoatrophy is associated with an increased risk of Hashimoto's thyroiditis and coeliac disease in female patients with type 1 diabetes. Horm Res Paediatr 2013: 79: 368-372.
88. Frid A, Hirsch L, Gaspar R et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010: 36 (Suppl. 2): S3-S18.
89. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996: 104: 106-110.
90. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002: 25: 634.
91. Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005: 28: 2025-2027.
92. De Silva BD, Schofield OM, Walker JD. The prevalence of necrobiosis lipoidica diabeticorum in children with type 1 diabetes. Br J Dermatol 1999: 141: 593-594.
93. Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol 2013: 69: 783-791.
94. Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking, and proteinuria. A case controlled study. Diabet Med 1993: 10: 725-728.
95. Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease. Pediatr Dermatol 1995: 12: 220-223.
96. Erfurt-Berge C, Seitz AT, Rehse C, Wollina U, Schwede K, Renner R. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients. Eur J Dermatol 2012: 22: 770-775.
97. Grgic A, Rosenbloom AL, Weber FT, Giordano B, Malone JI, Shuster JJ. Joint contracture - common manifestation of childhood diabetes mellitus. J Pediatr 1976: 88: 584-588.
98. Rosenbloom AL, Silverstein JH, Lezotte DC, Riley WJ, Maclaren NK. Limited joint mobility in diabetes mellitus of childhood: natural history and relationship to growth impairment. J Pediatr 1982: 101: 874-878.
99. Duffin AC, Donaghue KC, Potter M, McInnes A, Chan AK, King J, et al. Limited joint mobility in the hands and feet of adolescents with Type 1 diabetes. Diabetic Medicine. 1999; 16:125-130.
100. Craig ME, Duffin AC, Gallego PH, Lam A, Cusumano J, Hing S, et al. Plantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetes. Diabetes Care. 2008; 31:1201-1206.
101. Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L, Pollock BH. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr. 2001; 138:33-37.
102. Lindsay JR, Kennedy L, Atkinson AB, Bell PM, Carson DJ, McCance DR, et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care. 2005; 28:658-661.
103. Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 1981: 305: 191-194.
104. Hanna W, Friesen D, Bombardier C, Gladman D, Hanna A. Pathologic features of diabetic thick skin. J Am Acad Dermatol 1987: 16: 546-553.
105. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986: 314: 403-408.
106. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, et al. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 2012; 35:2331-2336.
107. Garg SK, Chase HP, Marshall G et al. Limited joint mobility in subjects with insulin dependent diabetes mellitus: relationship with eye and kidney complications. Arch Dis Child 1992: 67: 96-99.
108. Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998: 132: 944-947.
109. Aravamudhan A, Gardner C, Smith C, Senniappan S. Insulin oedema in a child with newly diagnosed diabetes mellitus. Eur J Pediatr 2014: 173: 685-687.
110. Baş VN, Çetinkaya S, Aǧladioǧlu SY et al. Insulin oedema in newly diagnosed type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2010: 2: 46-48.
111. Hirshberg B, Muszkat M, Marom T, Shalit M. Natural course of insulin edema. J Endocrinol Invest 2000: 23: 187-188.
112. Hopkins DF, Cotton SJ, Williams G. Effective treatment of insulin-induced edema using ephedrine. Diabetes Care 1993: 16: 1026-1028.
113. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007; 18:427-444.
114. Wedrychowicz A, Stec M, Sztefko K, Starzyk JB. Associations between Bone, Fat Tissue and Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2014.
115. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011: 96: 1911-1930.
116. Paxton GA, Teale GR, Nowson CA et al. Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. Med J Aust 2013: 198: 142-143.